Journal article · 2021 · Open access

A Critical Overview of FDA and EMA Statistical Methods to Compare In Vitro Drug Dissolution Profiles of Pharmaceutical Products

Jan Muselík, Alena Komersová, Kateřina Kubová, Kevin Matzick, Barbora Skalická

Pharmaceutics, 13(10), 1703 · Published 15 October 2021 · DOI 10.3390/pharmaceutics13101703

Free PDFView at the publisherCite this paper

In brief

“A Critical Overview of FDA and EMA Statistical Methods to Compare In Vitro Drug Dissolution Profiles of Pharmaceutical Products” is a 2021 journal article by Jan Muselík and 4 co-authors, published in Pharmaceutics. OpenAlex counts 119 citations as of 16 November 2026, which puts it in the top 1% of works published in 2021 by citations. It is open access under a CC BY licence: the full text is free to read at Pharmaceutics.

Citations
119
Most cited in
2024 (35)
Field-weighted impact
6.59
References
44
Authors
5

Abstract

A drug dissolution profile is one of the most critical dosage form characteristics with immediate and controlled drug release. Comparing the dissolution profiles of different pharmaceutical products plays a key role before starting the bioequivalence or stability studies. General recommendations for dissolution profile comparison are mentioned by the EMA and FDA guidelines. However, neither the EMA nor the FDA provides unambiguous instructions for comparing the dissolution curves, except for calculating the similarity factor f2. In agreement with the EMA and FDA strategy for comparing the dissolution profiles, this manuscript provides an overview of suitable statistical methods (CI derivation for f2 based on bootstrap, CI derivation for the difference between reference and test samples, Mahalanobis distance, model-dependent approach and maximum deviation method), their procedures and limitations. However, usage of statistical approaches for the above-described methods can be met with difficulties, especially when combined with the requirement of practice for robust and straightforward techniques for data evaluation. Therefore, the bootstrap to derive the CI for f2 or CI derivation for the difference between reference and test samples was selected as the method of choice.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Muselík, J., Komersová, A., Kubová, K., Matzick, K., & Skalická, B. (2021). A Critical Overview of FDA and EMA Statistical Methods to Compare In Vitro Drug Dissolution Profiles of Pharmaceutical Products. Pharmaceutics, 13(10), 1703. https://doi.org/10.3390/pharmaceutics13101703

MLA 9

Muselík, Jan, et al. “A Critical Overview of FDA and EMA Statistical Methods to Compare In Vitro Drug Dissolution Profiles of Pharmaceutical Products.” Pharmaceutics, vol. 13, no. 10, 2021, p. 1703. https://doi.org/10.3390/pharmaceutics13101703.

Chicago

Muselík, Jan, Alena Komersová, Kateřina Kubová, Kevin Matzick, and Barbora Skalická. 2021. “A Critical Overview of FDA and EMA Statistical Methods to Compare In Vitro Drug Dissolution Profiles of Pharmaceutical Products.” Pharmaceutics 13 (10): 1703. https://doi.org/10.3390/pharmaceutics13101703.

Harvard

Muselík, J. et al. (2021) ‘A Critical Overview of FDA and EMA Statistical Methods to Compare In Vitro Drug Dissolution Profiles of Pharmaceutical Products’, Pharmaceutics, 13(10), p. 1703. doi:10.3390/pharmaceutics13101703.

IEEE

J. Muselík, A. Komersová, K. Kubová, K. Matzick, and B. Skalická, “A Critical Overview of FDA and EMA Statistical Methods to Compare In Vitro Drug Dissolution Profiles of Pharmaceutical Products,” Pharmaceutics, vol. 13, no. 10, p. 1703, 2021, doi: 10.3390/pharmaceutics13101703.

BibTeX

@article{muselik2021critical,
  title     = {{A Critical Overview of FDA and EMA Statistical Methods to Compare In Vitro Drug Dissolution Profiles of Pharmaceutical Products}},
  author    = {Muselík, Jan and Komersová, Alena and Kubová, Kateřina and Matzick, Kevin and Skalická, Barbora},
  journal   = {Pharmaceutics},
  year      = {2021},
  volume    = {13},
  number    = {10},
  pages     = {1703},
  doi       = {10.3390/pharmaceutics13101703},
  url       = {https://doi.org/10.3390/pharmaceutics13101703}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20221515
20231515
20243535
20252424
20263030

Its field-weighted citation impact is 6.59: it has been cited 6.59 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems

  • in vitro dissolution
  • similarity factor f2
  • confidence interval estimation
  • bootstrapping
  • Mahalanobis distance
  • maximum deviation method
  • regulatory guidelines
  • FDA

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

Muselík, J., Komersová, A., Kubová, K., Matzick, K., & Skalická, B. (2021). A Critical Overview of FDA and EMA Statistical Methods to Compare In Vitro Drug Dissolution Profiles of Pharmaceutical Products. Pharmaceutics, 13(10), 1703. https://doi.org/10.3390/pharmaceutics13101703

How many times has this paper been cited?

119 times, according to OpenAlex on 16 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at Pharmaceutics.

Who wrote this paper?

Jan Muselík, Alena Komersová, Kateřina Kubová, Kevin Matzick, Barbora Skalická.

What is the DOI of this paper?

10.3390/pharmaceutics13101703. The permanent link is https://doi.org/10.3390/pharmaceutics13101703.

Bibliographic data from OpenAlex (CC0), last checked 16 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.